中国医药最新公告：子公司天方药业获得药品补充申请批准通知书

证券之星12-02

中国医药公告，其全资子公司天方药业收到国家药监局签发的两份盐酸托莫西汀胶囊《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。通知书同意增加25mg规格，核发药品批准文号，通过仿制药质量和疗效一致性评价。该药品用于治疗儿童和青少年的注意缺陷/多动障碍(ADHD)，2023年国内公立医院及公立基层医疗终端销售额约为3.18亿元，2024年上半年销售额约为1.51亿元。公司该药品2023年销售额约为59万元。

以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2488626508?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-02 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488626508","market":"hk","top_or_hot":-1,"title":"中国医药最新公告：子公司天方药业获得药品补充申请批准通知书","media":"证券之星","content":"<html><body><p><a href=\"https://laohu8.com/S/600056\">中国医药</a>公告，其全资子公司天方药业收到国家药监局签发的两份盐酸托莫西汀胶囊《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。通知书同意增加25mg规格，核发药品批准文号，通过仿制药质量和疗效一致性评价。该药品用于治疗儿童和青少年的注意缺陷/多动障碍(ADHD)，2023年国内公立医院及公立基层医疗终端销售额约为3.18亿元，2024年上半年销售额约为1.51亿元。公司该药品2023年销售额约为59万元。</p><p>以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中国医药最新公告：子公司天方药业获得药品补充申请批准通知书</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中国医药最新公告：子公司天方药业获得药品补充申请批准通知书\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-02 17:00 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2024120200021482.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中国医药公告，其全资子公司天方药业收到国家药监局签发的两份盐酸托莫西汀胶囊《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。通知书同意增加25mg规格，核发药品批准文号，通过仿制药质量和疗效一致性评价。该药品用于治疗儿童和青少年的注意缺陷/多动障碍(ADHD)，2023年国内公立医院及公立基层医疗终端销售额约为3.18亿元，2024年上半年销售额约为1.51亿元。公司该药品2023...</p>\n\n<a href=\"https://stock.stockstar.com/RB2024120200021482.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0082","symbol_name":"国资改革","start_time":0,"source_url":"https://stock.stockstar.com/RB2024120200021482.shtml","article_id":"2488626508","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488626508","pubTimestamp":1733130050,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"中国医药公告，其全资子公司天方药业收到国家药监局签发的两份盐酸托莫西汀胶囊《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。通知书同意增加25mg规格，核发药品批准文号，通过仿制药质量和疗效一致性评价。该药品用于治疗儿童和青少年的注意缺陷/多动障碍(ADHD)，2023年国内公立医院及公立基层医疗终端销售额约为3.18亿元，2024年上半年销售额约为1.51亿元。公司该药品2023年销售额约为59万元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600056":"中国医药","BK0082":"国资改革","BK0250":"批发","BK0010":"央企","BK0185":"二线龙头","BK0175":"白马股","BK0188":"融资融券","BK0028":"国家队"},"translate_title":"The latest announcement of China Pharmaceutical: Subsidiary Tianfang Pharmaceutical obtained the approval notice of supplementary drug application","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600056":1},"content_text":"中国医药公告，其全资子公司天方药业收到国家药监局签发的两份盐酸托莫西汀胶囊《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。通知书同意增加25mg规格，核发药品批准文号，通过仿制药质量和疗效一致性评价。该药品用于治疗儿童和青少年的注意缺陷/多动障碍(ADHD)，2023年国内公立医院及公立基层医疗终端销售额约为3.18亿元，2024年上半年销售额约为1.51亿元。公司该药品2023年销售额约为59万元。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2488626508"}